StockData
Sionna Therapeutics, Inc. logo

Sionna Therapeutics, Inc. (SION) stock

SIONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$2.97−0.10 (-3.26%)

Close on Nov 18, 2026Market cap $134.28MP/E –Yield –

Sionna Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Sionna Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$120.50M. For fiscal 2025 it was -$88.98M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$88.98M–
FY2024Dec 31, 2024-$70.56M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$34.82M–
Q2 FY2026Jun 30, 2026-$32.47M–
Q1 FY2026Mar 31, 2026-$29.60M–
Q4 FY2025Dec 31, 2025-$23.61M–
Q3 FY2025Sep 30, 2025-$23.81M–
Q2 FY2025Jun 30, 2025-$21.91M–
Q1 FY2025Mar 31, 2025-$19.66M–
Q4 FY2024Dec 31, 2024-$18.13M–
Q3 FY2024Sep 30, 2024-$27.98M–
Q2 FY2024Jun 30, 2024-$11.29M–
Q1 FY2024Mar 31, 2024-$13.15M–

More Sionna Therapeutics figures

See a number that looks wrong?